분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2012-01-22 18:29:27 , Hit : 2486
 Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans

Luke Timmerman1/19/12Leave a Comment


Cambridge,  MA-based Alnylam Pharmaceuticals is getting rid of about one-third of its workforce, as it looks to save cash for clinical trials that it hopes will prove the value of its RNA interference drug technology.

Alnylam (NASDAQ: ALNY) said today it’s cutting 33 percent of its staff, as it looks to concentrate its cash reserves on what it believes are its “highest value opportunities” in its pipeline of experimental RNAi drugs. The company didn’t disclose absolute numbers, but it said in its most recent quarterly report that it had 171 employees at the end of September, so if that number is still current, then 56 people are being let go, and about 115 people will remain at the company.

Alnylam has faced deep skepticism among investors in its RNAi platform, after scientists have struggled to effectively deliver the treatments into cells, and Big Pharma companies like Roche, Novartis, and Merck all scaled back their efforts in the field. But Alnylam, still relatively flush with cash from partnerships it struck years ago, has chosen to forge on by internally developing its own RNAi drugs for a group of liver diseases, where delivery is less of a challenge.

“As we effect our ongoing transformation from a platform company to a product company, now is the time to focus our near-term efforts and resources on what we believe to be our highest value opportunities,” said Alnylam CEO John Maraganore, in a statement.

Alnylam said the cuts are expected to save the company $20 million in cash this year. It ended 2011 with about $260 million of cash and investments in the bank, and said it plans next month to disclose its financial forecast for the coming year.

Alnylam has recently released some preliminary data from clinical trials of a couple RNAi programs that it says have emboldened it to push ahead and become a drug developer on its own. The first is for a rare liver disease called TTR amyloidosis, and the second is for high cholesterol, through hitting a biological target known as PCSK9. The company said today that as part of its restructuring, the TTR program, and another for hemophilia, are now its top two clinical priorities.

This isn’t the first time Alnylam has made layoffs. The company cut 25 to 30 percent of its workforce in September 2010 after Novartis ended a collaboration with the company.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.








827   Vertex study will evaluate 12-week treatment period for some hepatitis C patients  이성욱 2011/10/25 2886
826   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3643
825   Going Viral  이성욱 2011/10/28 2661
824   GlaxoSmithKline is first partner for new Alnylam platform  이성욱 2011/11/02 2578
823   Do Bacteria Age? Biologists Discover the Answer Follows Simple Economics  이성욱 2011/11/04 2436
822   Regular Aspirin Intake Halves Cancer Risk, Study Finds  이성욱 2011/11/04 2402
821   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2484
820   How Blood Cells Thwart Malaria  이성욱 2011/11/13 3417
819   Pox Vaccine Treats Liver Cancer - Smallpox vaccine extends life in cancer trial-  이성욱 2011/11/13 2688
818   AASLD: African-Americans Face Hep C 'Triple Whammy'  이성욱 2011/11/17 2409
817   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2611
816   Finger (mal)formation reveals surprise function of desert DNA  이성욱 2011/11/28 2765
815   Stem-cell pioneer bows out  이성욱 2011/11/28 2485
814   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2664
813   Treatment for Blood Disease Is Gene Therapy Landmark  이성욱 2011/12/13 2030
812   Vertex begins joint studies on hepatitis C compounds  이성욱 2011/12/13 2669
811   Former Reginans changing the future of HIV  이성욱 2011/12/28 2310
810   The RNA roots of obesity?  이성욱 2012/01/03 2291
  Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans  이성욱 2012/01/22 2486
808   Can DNA Self-replicate?  이성욱 2012/01/22 2492

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN